B+
Bull case
25%
Probability
Target price
$15.50
+59.5% vs current
AHCO
AdaptHealthDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$12.50
+28.6% vs current
B-
Bear case
30%
Probability
Target price
$8.50
-12.6% vs current
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+70.8
Score
AI commentary
Primary-source evidence is solid, but the read-through is mixed rather than cleanly bullish. The May 5, 2026 earnings release showed stronger revenue and a modest FY2026 revenue-guide increase, yet profitability and free cash flow disappointed enough that AHCO fell from $13.04 on May 4, 2026 to $11.75 on May 5, 2026 and to $10.74 by May 14, 2026 in a bounded market-data check. Secondary tracking pages indicate some post-print target increases, but analyst revision coverage remains thin, and there is no usable social-context packet here, so this stays a monitoring-style thesis.
RankAlpha Sentiment Codex - 2026-05-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystQ2 labor-cost normalization is the nearest margin repair testHigh impact
Management said the accelerated go-live for its new exclusive partner created about $12 million of elevated labor expense in Q1 2026, with the majority expected to normalize by the end of Q2. If that unwind shows up without disrupting growth, the post-earnings de-rating can partially reverse; if not, the margin debate likely persists. [#8-K-2026-05-05]
2026-08-01eventAugust 2026 note redemption remains a balance-sheet inflectionMedium impact
AdaptHealth completed a $1.1 billion refinancing in April 2026 and said the delayed-draw facility is intended to fund redemption of the 6.125% 2028 notes once callable at par in August 2026, which should lower interest cost and extend flexibility. The setup is favorable, but much of the financing improvement is already understood. [#10-Q-2026-05-05]
2026-12-31catalystCore portfolio simplification and digital scale need to convert into cleaner cash generationHigh impact
Q1 revenue grew 5.4% to $819.8 million with 9.1% organic growth, myApp users reached 412,000, and the company exited its remaining custom rehabilitation assets in April. The long-side case is that a simpler Sleep/Respiratory-focused portfolio plus digital self-service lifts margins and free cash flow in the back half of 2026; the bear case is that growth remains expensive and free cash flow stays volatile. [#8-K-2026-05-05] [#10-Q-2026-05-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology